Potential prognostic and predictive factors in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) treated with abiraterone acetate (AA) in daily clinical practice in Spain.

被引：0
|
作者：
Celiz, Pamela
Pinto, Alvaro
Puente, Javier
Manneh, Ray
Gonzalez Larriba, Jose Luis
Grande, Enrique
Alonso, Teresa
Manuel Sepulveda, Juan
Rodriguez, Alfredo
Castellano, Daniel E.
机构：
[1] Hosp 12 Octubre, E-28041 Madrid, Spain
[2] Hosp Univ La Paz, Madrid, Spain
[3] Hosp Clin Univ San Carlos, Madrid, Spain
[4] 12 Octubre Univ Hosp, Madrid, Spain
[5] Hosp Univ Ramon y Cajal, Dept Med Oncol, Madrid, Spain
[6] Ramon y Cajal Univ Hosp, Madrid, Spain
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2014年 / 32卷 / 15期
关键词：
D O I：
10.1200/jco.2014.32.15_suppl.e16074
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
e16074
引用
收藏
页数：1
相关论文
共 50 条
  • [1] Assessment of prognostic factors in metastatic castration-resistant prostate cancer (mCRPC) patients (pts) treated with abiraterone acetate (AA) after docetaxel (DOC).
    Cavaliere, Carla
    Caffo, Orazio
    Ortega, Cinzia
    D'aniello, Carmine
    Di Napoli, Marilena
    Cecere, Sabrina Chiara
    Della Pepa, Chiara
    Crispo, Anna
    Maines, Francesca
    Ruatta, Fiorella
    Iovane, Gelsomina
    Montella, Maurizio
    Pignata, Sandro
    Facchini, Gaetano
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [2] Population-based analysis of a novel prognostic model for metastatic castration-resistant prostate cancer (mCRPC) patients (pts) treated with abiraterone acetate (AA).
    Azad, Arun
    Lester, Renee
    Leibowitz-Amit, Raya
    Joshua, Anthony M.
    Heng, Daniel Yick Chin
    Eigl, Bernhard J.
    Chi, Kim N.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [3] Population-based analysis of a novel prognostic model for metastatic castration-resistant prostate cancer (mCRPC) patients (pts) treated with abiraterone acetate (AA)
    Azad, Arun
    Lester, Renee
    Leibowitz-Amit, Raya
    Joshua, Anthony Michael
    Heng, Daniel Yick Chin
    Eigl, Bernhard J.
    Chi, Kim N.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (04)
  • [4] ARN-509 in patients with metastatic castration-resistant prostate cancer (mCRPC) previously treated with abiraterone acetate (AA)
    Rathkopf, Dana E.
    Antonarakis, Emmanuel S.
    Shore, Neal D.
    Tutrone, Ronald
    Alumkal, Joshi J.
    Ryan, Charles J.
    Saleh, Mansoor N.
    Hauke, Ralph J.
    Bandekar, Rajesh
    Maneval, Edna Chow
    de Boer, Carla
    Todd, Mary
    Yu, Margaret K.
    Scher, Howard I.
    [J]. CANCER RESEARCH, 2014, 74 (19)
  • [5] A prognostic model for predicting overall survival (OS) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) treated with abiraterone acetate (AA) after docetaxel.
    Chi, Kim N.
    San Kheoh, Thian
    Ryan, Charles J.
    Molina, Arturo
    Bellmunt, Joaquim
    Vogelzang, Nicholas J.
    Rathkopf, Dana E.
    Fizazi, Karim
    Kantoff, Philip W.
    Li, Jinhui
    De Bono, Johann Sebastian
    Scher, Howard I.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [6] Evaluating the safety of abiraterone acetate (AA) and docetaxel (D) administered in combination in patients (Pts) with metastatic castration-resistant prostate cancer (mCRPC)
    Tagawa, Scott T.
    Nanus, David M.
    Posadas, Edwin M.
    Petrylak, Daniel Peter
    Bruce, Justine Yang
    Lim, Emerson A.
    Peng, Weimin
    Maul, Raymond Scott
    Gonzalez, Martha
    Tran, Namphuong
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (04)
  • [7] Prognostic index model (PIM) for overall survival (OS) in metastatic castration-resistant prostate cancer (mCRPC) patients (pts) without prior chemotherapy treated with abiraterone acetate (AA).
    Ryan, Charles J.
    Kheoh, Thian
    Li, Jinhui
    Molina, Arturo
    De Porre, Peter
    Carles, Joan
    Efstathiou, Eleni
    Kantoff, Philip W.
    Mulders, Peter F. A.
    Saad, Fred
    Griffin, Thomas W.
    Chi, Kim N.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [8] Retrospective analysis of prognostic factors for survival in metastatic castration-resistant prostate cancer patients (mCRPC) treated with abiraterone.
    Biro, Krisztina
    Budai, Barna
    Szonyi, Marta
    Bodrogi, Istvan
    Kuronya, Zsofia
    Gyergyay, Fruzsina
    Nagyivanyi, Krisztian
    Geczi, Lajos
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [9] Phase 1b study of abiraterone acetate (AA) and docetaxel (D) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC).
    Tagawa, Scott T.
    Posadas, Edwin M.
    Bruce, Justine Yang
    Lim, Emerson A.
    Petrylak, Daniel Peter
    Peng, Weimin
    Maul, Raymond Scott
    Smit, Hans W.
    Tran, Namphuong
    Nanus, David M.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [10] ARN-509 in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) with and without prior abiraterone acetate (AA) treatment.
    Rathkopf, Dana E.
    Antonarakis, Emmanuel S.
    Shore, Neal D.
    Tutrone, Ronald F.
    Alumkal, Joshi J.
    Ryan, Charles J.
    Saleh, Mansoor N.
    Hauke, Ralph J.
    Bandekar, Rajesh
    Maneval, Edna Chow
    De Boer, Carla
    Todd, Mary Beth
    Yu, Margaret K.
    Scher, Howard I.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
12345